Trial Profile

The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alunacedase alfa (Primary)
Indications Acute lung injury; Pulmonary arterial hypertension; Respiratory distress syndrome
Focus Therapeutic Use
Sponsors GlaxoSmithKline

Most Recent Events

25 Jan 2019 Status changed from recruiting to discontinued.
02 Oct 2018 Planned End Date changed from 3 May 2019 to 14 Jun 2019.
02 Oct 2018 Planned primary completion date changed from 3 May 2019 to 14 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com